Home / Concalls / Mitsu Chem Plast Limited

Mitsu Chem Plast Limited

Details

Mitsu Chem Plast Limited Q1FY27 Earnings Call Highlights

Financials

Business Background

Mitsu Chem Plast Limited, established in 1990, is an India-based plastic-processing company specializing in blow molding, injection molding and custom molding solutions. It operates four manufacturing facilities with over 32,450 MT of installed annual capacity and serves 700+ customers across sectors including pharmaceuticals, chemicals, food, agrochemicals, healthcare, automotive and FMCG. The company has 500+ SKUs, exports to 17 countries and has developed specialized capabilities in industrial packaging and hospital furniture parts. Its dedicated Furnastra brand caters to healthcare furniture components, while its R&D and value-engineering capabilities support customized and innovative product development. Mitsu was listed on the BSE SME Platform in 2016 and migrated to the BSE Main Board in 2020.


Q&A

Q1: What were the key financial highlights for Mitsu Chem Plast in Q1 FY27?

A: The company reported total income of ₹9,532.78 lakhs, a year-on-year growth of 11.62%. EBITDA grew significantly by 209.50% to ₹1,549.48 lakhs, with margins expanding to 16.29% from 5.87% in the previous year. Net profit rose by 566.23% to ₹873.83 lakhs, driven by improved operating efficiency and a better product mix.


Q2: What is the primary reason for the sharp improvement in EBITDA margins this quarter?

A: The margin improvement was driven by manufacturing and operating efficiencies, value engineering, and a stronger product mix. The company has also been focusing on higher value-added opportunities across packaging, healthcare, and furniture.


Q3: Is the current EBITDA margin of 16.29% sustainable in the long term?

A: While the company achieved over 16% this quarter due to specific high-margin products and efficiencies, management considers 10% to 12% (or 10% to 13%) as a sustainable "normal" range for the business. They aim to maintain double-digit margins consistently.


Q4: How is the company managing the impact of geopolitical situations on raw material costs?

A: The company has stopped importing raw materials and now sources locally in India, maintaining strong relationships with local producers. When suppliers increase prices due to global factors like crude oil fluctuations, the company successfully passes these increases on to its customers.


Q5: What is the status of the company’s capacity expansion plans?

A: Mitsu Chem Plast has proposed adding 3,550 metric tons to its existing capacity. This additional capacity is already operational and was announced after successful trial runs.


Q6: Why is the company increasing capacity when current utilization is only around 64%?

A: Management explained that because getting and commercializing machinery takes 6 to 9 months, they must plan ahead. Having the infrastructure ready allows them to capture future demand, and they consider 65% to 70% utilization as a healthy level for the company given seasonal variations.


Q7: Can you provide an update on the IBC (Intermediate Bulk Container) project?

A: The company expects to start commercial production for the IBC project in Q3. This is viewed as a significant new market opportunity requiring completely different, new machinery.


Q8: What is the company's strategy regarding SKU rationalization?

A: The company has already begun rationalizing low-volume and low-margin SKUs. They are moving away from "profit drainers" to focus production capacity on products that offer better margins, turnover, and throughput.


Q9: How aggressive is the company in acquiring new customers?

A: Customer acquisition is an ongoing process; the company added more than 30 new customers this quarter and added over 150 customers in the last year. They prioritize customers who provide better profitability and throughput.


Q10: Is the company still on track to reach its ₹1,000 crore revenue target by FY28?

A: Yes, management confirmed they are in line with the ₹1,000 crore annual revenue goal for FY28. While this quarter's revenue was relatively low, they expect revenue growth to accelerate as new projects like IBC come online.


Q11: What is the current contribution of exports to the total revenue?

A: Exports currently account for approximately 2% of total revenue. While the company has entered international markets and is working with global players, management noted that establishing products in these markets takes time.


Q12: Which product verticals are currently seeing the strongest demand?

A: Demand is strong across all three verticals: containers (packaging), furniture parts, and others. While packaging remains the largest segment (~80%), management expects significant growth in furniture parts moving forward.


Q13: What was the capital expenditure (CAPEX) required for the recent 3,550 MT expansion?

A: The CAPEX for this additional capacity was approximately ₹2 crores. The company uses a mix of internal accruals and debt to fund its expansion plans.


Q14: How does the company view its strategic focus shifting between top-line and bottom-line growth?

A: Management explicitly stated that they are now focusing more on the bottom line (profitability) rather than just the top line (revenue). This is being achieved through value addition, operational excellence, and sacrificing low-margin volumes where necessary.



Strategic Outlook

  1. Achieving the ₹1,000 crs revenue ambition by FY28 remains the company’s key long-term objective, with transformation centred around operational excellence, data-driven marketing, scientific innovation and empowered teams.
  2. Mitsu plans to expand Furnastra by developing advanced, design-forward hospital furniture solutions and strengthening the brand’s presence in the healthcare segment to capture additional market opportunities.
  3. Packaging remains another strategic priority, with higher production of pails, containers and jerrycans and greater focus on specialized caps and closures expected to expand the addressable product portfolio.
  4. The company is focused on increasing exports and international market presence, with operations already reaching 17 countries and export revenues of ₹3.35 cr reported for FY26.
  5. Sustainability is being integrated into operations through initiatives around energy and diesel consumption, water conservation, recycling of in-house waste and use of post-consumer resin, supporting the company’s responsible-growth approach.
  6. Mitsu intends to continue investing in talent, cross-functional collaboration and accountability while leveraging R&D and market analysis to introduce state-of-the-art products and strengthen its competitive positioning.


Business Strategy

  1. The company focuses on value-added plastic processing through blow molding, injection molding and custom molding, combining technical expertise, product innovation and value engineering to deliver customized solutions.
  2. Mitsu aims to strengthen its packaging business by increasing production of pails, containers and jerrycans, while building capabilities in specialized caps and closures to broaden its product offering.
  3. Healthcare is a key growth avenue through Furnastra, which provides design-oriented and customizable hospital furniture parts focused on innovation, durability, patient comfort and evolving healthcare requirements.
  4. The company intends to drive operational excellence by refining manufacturing processes, reducing waste and improving production speed and quality, thereby supporting efficiency and scalability.
  5. Mitsu plans to leverage targeted marketing and stronger customer engagement to enhance brand loyalty, supported by a diverse customer base spanning pharmaceuticals, agrochemicals, FMCG, food, healthcare, chemicals and other industries.
  6. In-house R&D, reverse engineering, design and prototyping capabilities support the company’s strategy of developing innovative products with clear economic benefits while maintaining a quality-first approach.


Key Highlights

  1. Mitsu Chem Plast reported Q1 FY27 revenue of ₹95.15 crs, up from ₹85.28 crs in Q1 FY26, while EBITDA increased sharply to ₹15.49 crs from ₹5.01 crs, improving EBITDA margin to 16.29% from 5.87%.
  2. Net profit rose significantly to ₹8.74 crs in Q1 FY27 from ₹1.31 crs in Q1 FY26, with net profit margin expanding to 9.18% from 1.54%. EPS increased to ₹6.44 from ₹0.97.
  3. The company has 35+ years of experience, 4 manufacturing facilities, 53 blow-molding and 22 injection-molding machines, with installed capacity of over 32,450 MT annually. It serves 700+ customers across 17 export countries.
  4. Mitsu offers blow molding, injection molding and custom molding solutions across pharma, chemicals, food, agrochemicals, healthcare, automotive and other industries, supported by a broad product portfolio of 500+ SKUs.
  5. The company has strengthened its healthcare presence through Furnastra, a dedicated brand for hospital furniture parts, while expanding its packaging portfolio through pails, containers, jerrycans and specialized caps and closures.
  6. Mitsu has set an ambitious target of achieving ₹1,000 crs annual revenue by FY28, representing a threefold increase over FY24, supported by operational excellence, data-driven marketing, scientific innovation and empowered teams.


Performance

Q1 FY27:

  1. Revenue from operations: ₹95.15 crs (↑11.57% YoY)
  2. EBITDA: ₹15.49 crs | EBITDA Margin: 16.29% (↑1,041 Bps)
  3. PAT: ₹8.74 crs | PAT Margin: 9.18% (↑765 Bps)


FY26:

  1. Revenue from operations: ₹350.17 crs
  2. EBITDA: ₹34.79 crs | EBITDA Margin: 9.93%
  3. PAT: ₹15.70 crs | PAT Margin: 4.48%


Disclaimer

This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. Recipients may not receive this report at the same time as other recipients. The information contained herein is from the public domain or sources are believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Opinions expressed are current opinions as of the date appearing on this material only. While we endeavour to update on a reasonable basis, the information discussed in this material, Mr Avinash Gorakshakar is under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Avinash Gorakshakar and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report. This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behaviour of investors or recipients or provide any investment/tax advice. This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis. Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital. Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of Avinash Gorakshakar. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

SEBI REGN NO. INH000001071